Insurance Barriers Limit Children’s Access to Biologics for Asthma
-
By
-
Debbie Bunch
-
November 16, 2026
Clinical Scorecard: Insurance Barriers Limit Children’s Access to Biologic Medications
At a Glance
Category | Detail |
|---|---|
Condition | Pediatric patients prescribed biologic medications by allergists |
Key Mechanisms | Insurer prior authorization, step-therapy requirements, and insurer eligibility criteria can delay or prevent access to prescribed biologics. |
Target Population | Children prescribed biologics by allergists; the study included 326 prescriptions for pediatric patients with a mean age of 11 years. |
Care Setting | Biologic prescriptions issued by allergists and reviewed by insurers. |
Key Highlights
The study examined 326 biologic prescriptions issued by allergists for pediatric patients from 2018 through 2026.
Omalizumab accounted for 55.8% of prescriptions, and dupilumab accounted for 26%.
Insurance approval was required before dispensing for nearly all prescriptions.
Approximately four in ten prescriptions were ultimately denied.
For children who ultimately received treatment, the interval from prescription to initiation generally exceeded one month.
Guideline-Based Recommendations
Diagnosis
Confirm the child’s diagnosis and clinical eligibility for the prescribed biologic using the relevant clinical criteria.
Management
When prescribing a biologic, account for insurer prior-authorization and step-therapy requirements, which may delay or prevent treatment.
Document the clinical rationale for the prescribed medication and provide information needed to support the authorization request.
Monitoring & Follow-up
Track authorization decisions and the time from prescription to treatment initiation; follow up on pending requests and denials.
For denied prescriptions, review the insurer’s stated reason, including requests for a different medication trial or a determination that eligibility criteria were not met.
Risks
Prior authorization, step-therapy requirements, and insurer eligibility criteria may delay or prevent access to prescribed biologics.
In this study, approximately four in ten prescriptions were denied, and treatment initiation for children who received therapy generally took more than one month after prescribing.
Patient & Prescribing Data
Pediatric patients prescribed biologics by allergists; mean age was 11 years, and approximately half were male.
Omalizumab was the most frequently prescribed biologic (55.8%), followed by dupilumab (26%). Nearly all prescriptions required prior insurance approval; approximately four in ten were denied, most commonly because insurers required a different medication trial first or determined that the child did not meet their criteria for the prescribed drug.
Clinical Best Practices
Anticipate insurer review when prescribing biologics, document the clinical rationale and relevant eligibility information, and promptly follow up on authorization requests and denials to help address access delays.
Related Resources & Content
Global Initiative for Asthma, GINA Strategy Report 2026 -- Global Strategy for Asthma Management and Prevention
mdspire news, Year not provided -- Distribution Barriers May Reduce Biologic Drug Survival
Pharmacoepidemiology and Drug Safety, Year not provided -- Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study
JAMA Network Open, Year not provided -- Population-Level Trends in Asthma Exacerbations After Introduction of Respiratory Biologics
RT, Year not provided -- Insurance Denials, Delays Limit Pediatric Asthma Biologics
ASCO Publications — ReCAP: Gaps in Insurance Coverage for Pediatric Patients With Acute Lymphoblastic Leukemia
GINA Strategy Report 2026
Insurance Denials, Delays Limit Pediatric Asthma Biologics
GINA Strategy Report 2026 Front Cover
DailyMed - XOLAIR- omalizumab injection, solution XOLAIR PFS- omalizumab injection, solution XOLAIR- omalizumab injection, solution
label
Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE)
Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)
Age-specific efficacy of biologics in severe asthma: a pediatric perspective
Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis
PRIOR AUTHORIZATION DISCREPANCIES AMONG STATE MEDICAID PROGRAMS FOR MEPOLIZUMAB
Based on findings from:
Insurance Companies Make It Difficult for Kids with Asthma to Get Biologics
Debbie Bunch. American Association For Respiratory Care, 2026.
https://rccentral.aarc.org/insurance-barriers-biologics-children-severe-asthma/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.